Introduction
============

Molecules possessing a chiral phosphorus([iii]{.smallcaps})[@cit1] as well as phosphorus([v]{.smallcaps}) center[@cit2] are important compounds classes with widespread applications. The catalytic and stereoselective synthesis of molecules with chiral phosphorus centers received significant attention,[@cit3] but remains a challenging task. Additional and complementary methods for their selective preparations are highly desirable and would be synthetically very valuable. In this respect, catalytic enantioselective C--H functionalizations have emerged a complementary tactic to access chiral building blocks from simple starting materials.[@cit4] To the best of our knowledge, the synthesis of P-stereogenic centers by catalytic C--H functionalizations is so far limited to desymmetrization reactions of achiral precursors.[@cit5] For instance, we have recently reported the formation of cyclic phosphinic amides catalyzed by chiral Cp^*x*^Rh^III^-catalysts.[@cit5g],[@cit6],[@cit7] This desymmetrization approach is only suitable for substrates containing the same two aromatic substituents with identical prochiral C--H groups, thus restricting the obtainable structural diversity. Notably, acyclic P-stereogenic phosphinic amides[@cit8] are not accessible by this approach.

Herein, we report a flexible route to new trisubstituted Cp^*x*^ ligands. We showcase their potential for an enantioselective Cp^*x*^Rh^III^-catalyzed C--H functionalization of racemic phosphinic amides through a kinetic resolution[@cit9] ([Scheme 1](#sch1){ref-type="fig"}). *s*-Factors of up to 50 were realized with the new tri-substituted Cp^*x*^ ligands, largely outperforming any previous Cp^*x*^ ligand.

![Rh^III^-catalyzed desymmetrization and kinetic resolution approaches for the synthesis P-chiral compounds.](c7sc05411d-s1){#sch1}

Conceptually, both acyclic starting material enantiomers can coordinate to the Cp^*x*^Rh^III^ catalyst forming diastereomeric intermediates **I** and **IV** ([Scheme 2](#sch2){ref-type="fig"}). In the subsequent -- likely rate-limiting step of the process -- the matching enantiomer would undergo C--H activation leading to rhodacycle **II** much faster than **IV** to **V**, corresponding to *k*~2~ ≫ *k*~5~. Experimental support of this assumption consists in the absence of *ortho*-C-deuteration of unreacted starting material (see ESI[†](#fn1){ref-type="fn"} for details). Rhodacycle **II** can further react with alkyne *via***III** to deliver cyclic phosphinic amide **2a**. The unreactive complex **IV** reverts back to the Rh^III^-catalyst and substrate **1a**. Over time, the reacting enantiomer is removed from the starting material, get enriched over time.

![Kinetic resolution by a difference in the cyclometalation rates *k*~2~ \> *k*~5~.](c7sc05411d-s2){#sch2}

Results and discussion
======================

The initial feasibility of the kinetic resolution was explored with racemic phenyl methyl phosphinic amide *rac*-**1a** and diphenyl acetylene ([Table 1](#tab1){ref-type="table"}). Complex **Rh1** with our standard second generation Cp^*x*^ ligand (R = OMe)[@cit10] caused a moderate rate difference in the reaction of the two starting material enantiomers, correlating to an *s*-factor of 14 (entry 1).[@cit11],[@cit12] Cp^*x*^ ligands with other substitutions R^10^ were largely inferior (entries 2--5). We hypothesized that a new trisubstituted Cp^*x*^ ligand class with increased bulk may enhance the selection between matched and mismatched substrate. These ligands are straightforward prepared from **L1** by condensation with a ketone forming the corresponding fulvenes **3** and **4** ([Scheme 3](#sch3){ref-type="fig"}).[@cit13] Reduction of **3** with LiAlH~4~ gave isopropyl-substituted ligand **L6**. X-ray crystallographic analysis of \[**L6**RhCl~2~\]~2~ showed the orientation of the installed isopropyl group.[@cit14] Moreover, facile addition of lithium organometallics across the fulvene double bond provided access to ligands **L7**-**L10** with bulky *tert*-butyl analogues as third Cp substituent. The corresponding rhodium complexes were subsequently evaluated for the kinetic resolution. In this respect, **Rh6** with an isopropyl group R′ largely improved the *s*-value to 32 (entry 6). **Rh7** featuring a larger *tert*-butyl group further improved the selectivity to an *s*-value of 42 (entry 7). **Rh8** and **Rh9** were slightly inferior (entries 8 and 9). **Rh10** featuring a 1-butylcyclohexyl group R′ allowed for a significant reduction in reaction time to 3 h maintaining a high *s* value of 41 (entry 10). Moreover, the amount of diphenyl acetylene could be lower to 0.6 equivalents, improving the selectivity further (entries 11--12).

###### Screening of the Cp^*x*^ ligands for the kinetic resolution[^*a*^](#tab1fna){ref-type="fn"}

  ![](c7sc05411d-u1.jpg){#ugr1}                                                                         
  ------------------------------------------ ---------- ----- ---- ------------------ ----------------- ----
  1                                          **Rh1**    8     54   91 : 9 (40)        85 : 15 (46)      14
  2                                          **Rh2**    10    60   78 : 22 (35)       81 : 19 (46)      4
  3                                          **Rh3**    32    30   63.5 : 36.5 (63)   84 : 16 (23)      4
  4                                          **Rh4**    32    18   57 : 43 (78)       77 : 23 (17)      5
  5                                          **Rh5**    32    54   68 : 32 (42)       76 : 24 (32)      3
  6                                          **Rh6**    10    55   98 : 2 (42)        89 : 11 (48)      32
  7                                          **Rh7**    8.5   51   95 : 5 (46)        93 : 7 (46)       42
  8                                          **Rh8**    5     55   98.5 : 1.5 (42)    89 : 11 (50)      36
  9                                          **Rh9**    3     53   96 : 4 (44)        90.5 : 9.5 (48)   32
  10                                         **Rh10**   3     55   99 : 1 (42)        90.5 : 9.5 (48)   41
  11[^*d*^](#tab1fnd){ref-type="table-fn"}   **Rh7**    8.5   52   97 : 3 (44)        93 : 7 (48)       50
  12[^*d*^](#tab1fnd){ref-type="table-fn"}   **Rh10**   4     51   95.5 : 4.5 (46)    94 : 6 (46)       47

^*a*^Conditions: 50 μmol **1a**, 75 μmol **5a**, 5.0 μmol **Rh7**, 5.0 μmol (BzO)~2~, 0.10 mmol Ag~2~CO~3~, 50 μmol K~2~CO~3~, 0.25 [m]{.smallcaps} in *t*BuOH at 90 °C for the indicated time; Ar = 3,5-(CF~3~)C~6~H~3~.

^*b*^By 1H-NMR.

^*c*^By chiral HPLC, (isolated yield).

^*d*^With 30 μmol **5a**.

![Synthesis of trisubstituted **L6--L10** from **L1**.](c7sc05411d-s3){#sch3}

Next, the scope of the kinetic resolution procedure was evaluated ([Table 2](#tab2){ref-type="table"}). Steric and electronic variations of R on the aryl group in the *para*- and *meta*-position had little influence on the reaction performance (entries 1--8). In all cases, the reaction of *rac*-**1a--1h** could be stopped at around 50% conversion. Both products were isolated in good to excellent enantioselectivities, resulting in *s*-values ranging from 26--50. An *ortho*-substituted aryl group (*rac*-**1i**) largely equalled the reaction rates of both starting material enantiomers and reduced the *s*-values. Besides variations of the aryl group, substituent R′ can be varied, maintaining synthetically useful selectivities (entries 10--11). In addition to phosphinic amides, we evaluated phosphonodiamidates *rac*-**1l** and *rac*-**1m** (entries 12--13) as well as phosphonamidate esters *rac*-**1n** and *rac*-**1o** (entries 14--15) towards the resolutions conditions.[@cit15] The additional hetero atom on the phosphorus center had only a weak influence on the reactivity, whereas the *s*-values were lower with the current ligand system.

###### Kinetic resolution of aryl phosphinic amides *rac*-**1**[^*a*^](#tab2fna){ref-type="fn"}

  ![](c7sc05411d-u2.jpg){#ugr2}                                                                                             
  ------------------------------------------ --------------- ----------------- ------ ---- ----------------- -------------- ----
  1                                          *rac-* **1a**   H/Me              8.5    51   95 : 5 (46)       93 : 7 (46)    42
  2                                          *rac-* **1b**   4-Me/Me           10.5   55   98 : 2 (42)       89 : 11 (50)   32
  3                                          *rac-* **1c**   4-F/Me            10.5   55   98 : 2 (40)       90 : 10 (48)   32
  4                                          *rac-* **1d**   4-Cl/Me           10.5   55   97 : 3 (40)       89 : 11 (45)   29
  5                                          *rac-* **1e**   4-OMe/Me          8.5    54   99 : 1 (42)       91 : 9 (48)    50
  6                                          *rac-* **1f**   4-NMe~2~/Me       9.5    42   83 : 17 (50)      95 : 5 (36)    43
  7                                          *rac-* **1g**   3-Me/Me           10.5   58   99 : 1 (38)       85 : 15 (53)   26
  8                                          *rac-* **1h**   3-Br/Me           14     55   99 : 1 (38)       91 : 9 (42)    49
  9                                          *rac-* **1i**   2-Me/Me           10     53   79 : 21 (44)      77 : 23 (42)   5
  10                                         *rac-* **1j**   H/Bn              4      59   99.5 : 0.5 (37)   84 : 16 (53)   27
  11                                         *rac-* **1k**   H/(CH~2~)~2~OBn   6.5    51   93 : 7 (44)       93 : 7 (47)    29
  12                                         *rac-* **1l**   H/pyrrolidinyl    5      57   89 : 11 (40)      79 : 21 (52)   9
  13                                         *rac-* **1m**   H/morpholinyl     3.5    61   95 : 5 (37)       79 : 21 (55)   11
  14[^*d*^](#tab2fnd){ref-type="table-fn"}   *rac-* **1n**   H/OMe             24     60   97 : 3 (37)       81 : 19 (55)   15
  15[^*d*^](#tab2fnd){ref-type="table-fn"}   *rac-* **1o**   H/OPh             14     53   91 : 9 (44)       86 : 14 (48)   16

^*a*^Conditions: 0.10 mmol **1a**, 0.15 mmol **5a**, 10 μmol **Rh7**, 10 μmol (BzO)~2~, 0.20 mmol Ag~2~CO~3~, 0.10 mmol K~2~CO~3~, 0.25 [m]{.smallcaps} in *t*BuOH at 90 °C; Ar = 3,5-(CF~3~)C~6~H~3~.

^*b*^By ^1^H-NMR.

^*c*^By chiral HPLC, (isolated yield).

^*d*^At 70 °C.

The nature of alkyne **5** can be varied as well ([Table 3](#tab3){ref-type="table"}). Whereas electron-rich diaryl alkyne **5b** reacted less selective, unsymmetrically substituted internal alkynes such as **5c**, **5d** and **5e** provided comparable selectivities. Moreover, they are incorporated in a highly regioselective manner, giving **2ac**, **2ad** and **2ae** with excellent regioselectivities.

###### Variation of the alkyne **5**[^*a*^](#tab3fna){ref-type="fn"}

  ![](c7sc05411d-u3.jpg){#ugr3}                                                                                                                          
  ------------------------------- -------- ----- ------------------------------- ---- -------------- --------------------------------------------------- ----
  1                               **5a**   Ph    Ph                              51   95 : 5 (46)    93 : 7 (46)                                         42
  2                               **5b**   PMP   PMP                             51   90 : 10 (46)   89 : 11 (46)                                        18
  3                               **5c**   Bu    PMP                             50   94 : 6 (46)    95 : 5 (46)[^*d*^](#tab3fnd){ref-type="table-fn"}   45
  4                               **5d**   iPr   PMP                             43   82 : 18 (52)   94 : 6 (37)[^*e*^](#tab3fne){ref-type="table-fn"}   23
  5                               **5e**   Bu    ![](c7sc05411d-u4.jpg){#ugr4}   54   98 : 2 (43)    96 : 4 (48)[^*e*^](#tab3fne){ref-type="table-fn"}   39

^*a*^Conditions: 0.10 mmol **1a**, 0.15 mmol **5a--d**, 10 μmol **Rh7**, 10 μmol (BzO)~2~, 0.20 mmol Ag~2~CO~3~, 0.10 mmol K~2~CO~3~, 0.25 [m]{.smallcaps} in *t*BuOH at 90 °C for 8.5 h; Ar = 3,5-(CF~3~)C~6~H~3~.

^*b*^By ^1^H-NMR.

^*c*^By chiral HPLC, (isolated yield).

^*d*^rs = 18 : 1.

^*e*^rs ≥ 20 : 1.

In addition, we have as well investigated racemic phosphinic amide substrate *rac*-**1p** having two different aryl groups (eqn (1)). In this case, a parallel kinetic resolution[@cit16] becomes operative, yielding the two cyclic phosphinic amide products **2p** and **2p′** in excellent yield and good enantioselectivity.

The P-chiral phosphinic amides were subsequently evaluated as chiral Lewis-bases in enantioselective reductive aldol additions[@cit17] between enone **6** and benzaldehyde ([Scheme 4](#sch4){ref-type="fig"}). Aldol adduct *syn*-**7** was obtained in 96 : 4 er with 13 : 1 *syn*/*anti* ratio using methyl-substituted **2a** as the catalyst. In stark contrast, related phenyl-substituted phosphinic amide **8** obtained by the previous desymmetrization method[@cit5g] provided isomer *anti*-**7** preferentially (1 : 4 *syn*/*anti*), with almost no enantioselectivity. Moreover, an enantiospecific access to corresponding P^III^-compound was achieved by transfer reduction with P(NMe~2~)~3~*via* its thiophosphinic amide **9**,[@cit18] providing **10** in 90% yield and 99.5: 0.5 er with retention of the configuration. Subsequent use of **10** as a ligand in rhodium catalyzed asymmetric hydrogenation[@cit19] of **11** provided reduced product **12** in 99% yield and 86 : 14 er.

![(I) Comparison of phosphinamides **2a** and **8** in enantioselective reductive aldol reactions. (II) Enantiospecific reduction of **2a** (**2a**: \>99.5 : 0.5 er). (III) Rh-catalyzed asymmetric hydrogenation with **10** as chiral ligand.](c7sc05411d-s4){#sch4}

Conclusions
===========

In summary, we have developed a new trisubstituted Cp^*x*^ ligand family. Based on our atropchiral Cp^*x*^ ligand scaffold, we have shown that the introduction of a bulky third substituent at the central position of the Cp ring leads to substantially increased selectivities for kinetic resolutions and allowed for *s*-factors of up to 50. The superiority of them are showcased by kinetic resolutions amides providing access to compounds with stereogenic phosphorus([v]{.smallcaps}) atoms. The ligand synthesis capitalizes on a late stage modification and expands the accessible ligand Cp^*x*^ ligand portfolio for further catalytic-enantioselective transformations with additional metals.
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